AstraZeneca reports that its sales increase in the first half of 2026, citing stronger demand for cancer treatments. The company says total revenues for the six-month period reach $30.67 billion, reflecting growth compared with prior performance. Coverage of the results links the increase to higher demand across the company’s oncology-focused portfolio, which includes products used in cancer prevention, diagnosis, and treatment. The Belfast Telegraph and The Independent both describe the same overall direction of the results—higher revenue driven by oncology demand—while The Independent provides the specific figure for total revenues. The reporting focuses on revenue and the demand environment for cancer therapies, without detailing individual product performance or regional breakdowns in the information provided. The results are presented as part of AstraZeneca’s ongoing financial reporting for mid-year 2026, with the company attributing the sales improvement primarily to oncology treatment demand.